Table 3.

Baseline clinical and demographic data stratified by cardiac death during follow-up. Values represent the mean ± 1 S.D.

	Male Patients			Female Patients
	Survivors	Deaths	p Value†	Survivors	Deaths	p Value††
Age (years)	61±11	66±11	<.001	63±12	63±12	.968
Minority, %	18	14	.492	28	44	.059
Obesity, %	38	38	.468	48	47	.883
Diabetes, %	32	45	.056	46	63	.070
Smoking history, %	78	77	.892	58	47	.232
% smoking	20	12	.197	25	33	.472
3-vessel CAD, %	45	71	<.001	34	41	.448
ICD, %	2	13	<.001	2	19	<.001
LVEF (%)	51±12	44±15	<.001	54±10	45±17	<.001
CHF, %	16	38	<.001	25	63	<.001
Medications:
Beta-blockers	81	75	.239	79	72	.358
Diuretics	29	54	<.001	47	66	.048
Antidepressants	16	20	.517	29	38	.334
Benzodiazepines	11	21	.019	12	22	.141
Psychological Measures
Phobic anxiety score	2.5 ± 2.3	2.3 ± 2.7	.666	3.9 ± 3.2	5.7 ± 3.2	.003
BDI score	6.7 ± 6.0	7.9 ± 7.0	.164	8.2 ± 7.0	11.9 ± 9.5	.008
Parasympathetic Cardiac Control
HF power (ln msec2)	4.9±1.1	4.7±1.1	.180	5.1±1.2	4.6±1.4	.030

Abbreviations: ICD. implantable cardioverter defibrillator; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; CHF, congestive heart failure; BDI, Beck Depression Inventory; HF, high frequency

^†p-value reflects the contrast between survivors and deaths in male patients

^††p-value reflects the contrast between survivors and deaths in female patients